Related Experiment Video
Updated: Oct 7, 2025
14:51
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
Published on: June 17, 2022
3.3K
Checkpoint Blockade + Chemotherapy: the Right Combination for AML?
Spencer C Wei1, James J Mancuso2, Naval Daver3
1Spotlight Therapeutics, Hayward, California. spencer.wei@spotlighttx.com jallison@mdanderson.org.
Blood Cancer Discovery
|January 11, 2022
Summary
Combining cytotoxic therapies with immune checkpoint blockade can improve cancer treatment. Understanding how these agents affect immune cells is key to maximizing treatment effectiveness and minimizing side effects.
Area of Science:
- Oncology
- Immunotherapy
- Cancer Research
Background:
- Relapsed/refractory cancers often resist standard treatments.
- Immune checkpoint blockade (ICB) is a promising cancer therapy.
- Enhancing ICB efficacy through combination strategies is under investigation.
Purpose of the Study:
- To explore the combination of cytotoxic therapies and ICB for relapsed/refractory cancers.
- To understand the impact of these combined agents on immune cell populations.
- To facilitate the rational design of combination therapies for improved outcomes.
Main Methods:
- Investigating the effects of cytotoxic agents on cancer cells to induce immunogenic cell death.
- Analyzing immune cell responses and dynamics following combination treatment.
- Evaluating treatment efficacy and toxicity in preclinical models.
Main Results:
- Combination therapy can enhance immunogenic cell death, making tumors more susceptible to immune attack.
- Specific immune cell populations are modulated by the combined cytotoxic and immunotherapeutic agents.
- Data provides insights into the mechanisms underlying combination therapy efficacy.
Conclusions:
- Combining cytotoxic therapies with ICB is a viable strategy for overcoming resistance in relapsed/refractory cancers.
- Understanding immune cell modulation is critical for optimizing combination therapy design.
- This approach holds potential for maximizing therapeutic benefits while minimizing adverse effects.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
5.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.2K
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
526
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
526
02:57Targeted Cancer Therapies
7.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.9K
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
284
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
284
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
376
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
376